The latest financial statement is for the quarter ending 2025-11-30.
| Cash Flow | 2025-11-30 | 2025-08-31 |
|---|---|---|
| Net (loss) income | -22,607 | -5,540 |
| Depreciation | 9 | - |
| Amortization and depreciation | - | 4 |
| Standby equity purchase agreement non-cash commitment fee | 300 | - |
| Stock-based compensation | 183 | 179 |
| Prepaid expenses and other assets | -193 | -1,989 |
| Accounts payable, accrued expenses, and other liabilities | 17,576 | 918 |
| Net cash (used in) provided by operating activities | -4,350 | -2,450 |
| Proceeds from exercise of stock options | 0 | 21 |
| Cash paid for note payable | 0 | 142 |
| Net cash (used in) provided by financing activities | 0 | -121 |
| Net change in cash and cash equivalents | -4,350 | -2,571 |
| Cash and cash equivalents at beginning of period | 9,332 | 11,903 |
| Cash and cash equivalents at end of period | 4,982 | 9,332 |
CytoDyn Inc. (CYDY)
CytoDyn Inc. (CYDY)